These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 12131349)
1. Expression and prognostic value Of CD44 isoforms in nephroblastoma (Wilms tumor). Ghanem MA; Van Steenbrugge GJ; Van Der Kwast TH; Sudaryo MK; Noordzij MA; Nijman RJ J Urol; 2002 Aug; 168(2):681-6. PubMed ID: 12131349 [TBL] [Abstract][Full Text] [Related]
2. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753 [TBL] [Abstract][Full Text] [Related]
3. Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma. Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Oomen MH; Noordzij MA; Van den Heuvel MM; Nassef SM; Nijman RM; Van Steenbrugge GJ Clin Cancer Res; 2000 Nov; 6(11):4265-71. PubMed ID: 11106242 [TBL] [Abstract][Full Text] [Related]
4. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Ashida K; Terada T; Kitamura Y; Kaibara N Hepatology; 1998 Apr; 27(4):974-82. PubMed ID: 9537436 [TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma. Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Van den Heuvel MM; Noordzij MA; Nijman RJ; Soliman EH; van Steenbrugge GJ Br J Cancer; 2001 Nov; 85(10):1557-63. PubMed ID: 11720445 [TBL] [Abstract][Full Text] [Related]
6. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor. Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957 [TBL] [Abstract][Full Text] [Related]
7. The expression of HSP70 and HSP90alpha in children with Wilms tumor. Yang Y; Niu ZB; Hou Y; Wang CL J Pediatr Surg; 2006 Jun; 41(6):1062-6. PubMed ID: 16769335 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of CD44 molecule in renal cell carcinoma. Lucin K; Matusan K; Dordević G; Stipić D Croat Med J; 2004 Dec; 45(6):703-8. PubMed ID: 15578803 [TBL] [Abstract][Full Text] [Related]
9. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer. Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810 [TBL] [Abstract][Full Text] [Related]
10. The significance of VEGF-C/VEGFR-2 interaction in the neovascularization and prognosis of nephroblastoma (Wilms' tumour). Nowicki M; Ostalska-Nowicka D; Kaczmarek M; Miskowiak B; Witt M Histopathology; 2007 Feb; 50(3):358-64. PubMed ID: 17257131 [TBL] [Abstract][Full Text] [Related]
11. [Nephroblastomas (Wilms' tumors) and special variations of nephroblastomas]. Schmidt D Veroff Pathol; 1989; 133():1-174. PubMed ID: 2556868 [TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic value of CD44 isoforms in transitional cell carcinoma of renal pelvis and ureter. Masuda M; Takano Y; Iki M; Makiyama K; Noguchi S; Hosaka M J Urol; 1999 Mar; 161(3):805-8; discussion 808-9. PubMed ID: 10022688 [TBL] [Abstract][Full Text] [Related]
13. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor. Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629 [TBL] [Abstract][Full Text] [Related]
14. Examination of expression of WT1 gene product and CD44 adhesive molecule in nephroblastoma histologic types. Taran K; Kobos J; Sporny S Pol J Pathol; 2008; 59(3):177-82. PubMed ID: 19097357 [TBL] [Abstract][Full Text] [Related]
15. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Diaz LK; Zhou X; Wright ET; Cristofanilli M; Smith T; Yang Y; Sneige N; Sahin A; Gilcrease MZ Clin Cancer Res; 2005 May; 11(9):3309-14. PubMed ID: 15867228 [TBL] [Abstract][Full Text] [Related]
16. Differential expression of CD44 variant isoforms by cell lines and tissue specimens of transitional cell carcinomas. Chuang CK; Liao SK Anticancer Res; 2003; 23(6C):4635-9. PubMed ID: 14981907 [TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Ghanem MA; Van Der Kwast TH; Den Hollander JC; Sudaryo MK; Mathoera RB; Van den Heuvel MM; Noordzij MA; Nijman RJ; van Steenbrugge GJ Cancer; 2001 Dec; 92(12):3120-9. PubMed ID: 11753991 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of immunohistochemically detected CD44 expression in patients with carcinoma of the vulva. Tempfer C; Gitsch G; Haeusler G; Reinthaller A; Koelbl H; Kainz C Cancer; 1996 Jul; 78(2):273-7. PubMed ID: 8674003 [TBL] [Abstract][Full Text] [Related]
19. Expression of CD44(v5-10) splicing variants in primary ovarian cancer and lymph node metastases. Schröder W; Rudlowski C; Biesterfeld S; Knobloch C; Hauptmann S; Rath W Anticancer Res; 1999; 19(5B):3901-6. PubMed ID: 10628329 [TBL] [Abstract][Full Text] [Related]
20. Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma. Böhm JP; Niskanen LK; Pirinen RT; Kiraly K; Kellokoski JK; Moisio KI; Eskelinen MJ; Tulla HE; Hollmen S; Alhava EM; Kosma VM J Pathol; 2000 Nov; 192(3):321-7. PubMed ID: 11054715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]